Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1Phase 2 1

Status

Terminated 1Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4Gynecologic 2Thoracic 1Sarcoma 1Head & Neck 1Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 213Lung Neoplasms 79Triple Negative Breast Neoplasms 67Breast Neoplasms 67Ovarian Neoplasms 56Squamous Cell Carcinoma of Head and Neck 49Small Cell Lung Carcinoma 47Fallopian Tube Neoplasms 37Endometrial Neoplasms 34Neoplasms 31Parkinson Disease 4, Autosomal Dominant Lewy Body 28Neoplasm Metastasis 28Head and Neck Neoplasms 24Prostatic Neoplasms 20Carcinoma 19Esophageal Neoplasms 18Urinary Bladder Neoplasms 16Colorectal Neoplasms 16Uterine Cervical Neoplasms 15Oropharyngeal Neoplasms 14Carcinoma, Transitional Cell 14Carcinoma, Squamous Cell 14Esophageal Squamous Cell Carcinoma 13Brain Neoplasms 12Stomach Neoplasms 10Pancreatic Neoplasms 10Lymphoma, Large B-Cell, Diffuse 10Mouth Neoplasms 9Laryngeal Neoplasms 9Carcinoma, Ovarian Epithelial 9

Interventions

Fluorouracil 16Oxaliplatin 14Nivolumab 14Leucovorin 13pembrolizumab 9Paclitaxel 9Capecitabine 9Radiotherapy 6Radiation 6durvalumab 5Taxes 5Irinotecan 5Cisplatin 5Trastuzumab 4Specimen Handling 4Drug Therapy 4Carboplatin 4tremelimumab 3dehydroftorafur 3Ramucirumab 3Magnetic Resonance Spectroscopy 3Folfox protocol 3Endoscopy 3Docetaxel 3Biopsy 3zimberelimab 2zanidatamab 2trastuzumab deruxtecan 2tislelizumab 2futibatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Adenocarcinoma Of Esophagus × Carboplatin × 1 year × Clear all
NCT01196390 2026-06-02

Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer

National Cancer Institute (NCI)

Phase 3 Completed
203 enrolled 22 charts
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms

NCT04389632 2026-05-11

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

Seagen Inc.

Phase 1 Recruiting
1,006 enrolled
GastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms

NCT05252416 2025-11-28

(VELA) Study of BLU-222 in Advanced Solid Tumors

Blueprint Medicines Corporation

Phase 1 Terminated
50 enrolled
GastrointestinalGynecologicSarcoma

Adenocarcinoma Of Esophagus, Carcinosarcoma, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT04929392 2025-09-04

Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer

City of Hope Medical Center

Phase 2 Active not recruiting
3 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡